Both medications embody a innovative class of immunoglobulin treatments designed to neutralize the COVID-19 agent. Initially , sotrovimab, engineered by GSK , demonstrated considerable benefit against https://gregorygrqs669571.aboutyoublog.com/53768131/sotrovimab-vir-7831-a-deep-investigation-into-the-antibody-treatment